Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Cadrenal Therapeutics, Inc.CVKD · Entity 8251 | Director | October 09, 2026 | October 13, 2026 |
| MetaVia Inc.GEMP · Entity 7947 | Chief Medical Officer | January 28, 2018 | January 30, 2018 |
| PTC THERAPEUTICS, INC.PTCT · Entity 3803 | EVP & CHIEF MEDICAL OFFICER | April 02, 2026 | April 06, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Cadrenal Therapeutics, Inc.
Report date October 09, 2026 · Filed October 13, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $0.91 · Expires 2036-10-08 | Direct | 75,000 |
Reported balance
After 2026-10-09 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-10-09 · Grant · Acquired 75,000 · Balance 75,000 F1: The stock options have a grant date of October 9, 2026 under the Issuer's 2022 Successor Equity Incentive Plan, were fully vested and immediately exercisable on the date of grant, and have an exercise price equal to the closing price of the Issuer's common stock on October 9, 2026. |
Filing footnotes · ownership attribution and instrument terms
F1: The stock options have a grant date of October 9, 2026 under the Issuer's 2022 Successor Equity Incentive Plan, were fully vested and immediately exercisable on the date of grant, and have an exercise price equal to the closing price of the Issuer's common stock on October 9, 2026.
MetaVia Inc.
Report date January 28, 2018 · Filed January 30, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $10.10 · Expires 2028-01-27 | Direct | 148,000 |
Reported balance
After 2018-01-28 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2018-01-28 · Grant · Acquired 148,000 · Balance 148,000 F1: The option vests in a series of 48 successive monthly installments on the last day of each month, commencing on the grant date. |
Filing footnotes · ownership attribution and instrument terms
F1: The option vests in a series of 48 successive monthly installments on the last day of each month, commencing on the grant date.
PTC THERAPEUTICS, INC.
Report date April 02, 2026 · Filed April 06, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 79,115 |
Reported balance
After 2026-04-02 transaction · row 1
1 source rowRow 1 · 2026-04-02 · Sale · Disposed 829 · Balance 79,115 F1: Represents shares automatically sold pursuant to an irrevocable sell to cover election entered into upon acceptance of the grant to satisfy tax withholding obligations in connection with the vesting of 2,100 RSUs from an April 24, 2023 grant of 8,400 RSUs. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares automatically sold pursuant to an irrevocable sell to cover election entered into upon acceptance of the grant to satisfy tax withholding obligations in connection with the vesting of 2,100 RSUs from an April 24, 2023 grant of 8,400 RSUs.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 09, 2026 Filed Oct 13, 2026 21:33 UTC | Cadrenal Therapeutics, Inc. CVKD · Entity 8251 | GrantStock Option · Derivative | 75,000 | $0.00 Strike: $0.91 | $0.00 |
DisclosureSEC source: 0001213900-26-109131 · ownership.xml · derivative · entry 1 Golden Lee Scott · CIK 0001686217 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 75,000 Underlying: Common Stock · 75,000 shares Expires 2036-10-08 F1 · shares: The stock options have a grant date of October 9, 2026 under the Issuer's 2022 Successor Equity Incentive Plan, were fully vested and immediately exercisable on the date of grant, and have an exercise price equal to the closing price of the Issuer's common stock on October 9, 2026. F1 · derivative.exercise_date: The stock options have a grant date of October 9, 2026 under the Issuer's 2022 Successor Equity Incentive Plan, were fully vested and immediately exercisable on the date of grant, and have an exercise price equal to the closing price of the Issuer's common stock on October 9, 2026. Read SEC document |
| April 02, 2026 Filed Apr 6, 2026 21:20 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 829 | $67.99 | $56,363.71 |
DisclosureSEC source: 0001686217-26-000012 · form4-04062026_050401.xml · nonDerivative · entry 1 Golden Lee Scott · CIK 0001686217 · EVP & CHIEF MEDICAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 79,115 F1 · kind: Represents shares automatically sold pursuant to an irrevocable sell to cover election entered into upon acceptance of the grant to satisfy tax withholding obligations in connection with the vesting of 2,100 RSUs from an April 24, 2023 grant of 8,400 RSUs. Read SEC document |
| March 05, 2026 Filed Mar 9, 2026 21:20 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 10,000 | $63.38 | $633,800.00 |
DisclosureSEC source: 0001686217-26-000010 · form4-03092026_050303.xml · nonDerivative · entry 1 Golden Lee Scott · CIK 0001686217 · EVP & CHIEF MEDICAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 79,944 F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the reporting person on December 4, 2025. Read SEC document |
| February 18, 2026 Filed Feb 20, 2026 22:20 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 2,484 | $69.36 | $172,290.24 |
DisclosureSEC source: 0001686217-26-000008 · form4-02202026_050203.xml · nonDerivative · entry 1 Golden Lee Scott · CIK 0001686217 · EVP & CHIEF MEDICAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 89,944 F1 · shares: Represents shares automatically sold pursuant to an irrevocable sell to cover election entered into upon acceptance of the grant to satisfy tax withholding obligations in connection with the vesting of 5,000 RSUs from a February 15, 2024 grant of 20,000 RSUs and the vesting of 1,300 RSUs from a February 15, 2024 grant of 2,600 RSUs. Read SEC document |
| January 08, 2026 Filed Jan 12, 2026 22:20 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 866 | $76.45 | $66,205.70 |
DisclosureSEC source: 0001686217-26-000006 · form4-01122026_050105.xml · nonDerivative · entry 1 Golden Lee Scott · CIK 0001686217 · EVP & CHIEF MEDICAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 92,428 F1 · shares: Represents shares automatically sold pursuant to irrevocable sell to cover elections entered into upon acceptance of the respective grants to satisfy tax withholding obligations in connection with the vesting of 3,539 RSUs from January 7, 2022 grants totaling 14,155 RSUs. Read SEC document |
| January 07, 2026 Filed Jan 8, 2026 22:20 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 642 | $77.48 | $49,742.16 |
DisclosureSEC source: 0001686217-26-000004 · form4-01082026_050106.xml · nonDerivative · entry 2 Golden Lee Scott · CIK 0001686217 · EVP & CHIEF MEDICAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 93,294 F2 · shares: Represents shares automatically sold pursuant to an irrevocable sell to cover election entered into upon acceptance of the grant to satisfy tax withholding obligations in connection with the vesting of 2,666 RSUs from a January 5, 2023 grant of 10,640 RSUs. Read SEC document |
| January 06, 2026 Filed Jan 8, 2026 22:20 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 1,340 | $76.95 | $103,113.00 |
DisclosureSEC source: 0001686217-26-000004 · form4-01082026_050106.xml · nonDerivative · entry 1 Golden Lee Scott · CIK 0001686217 · EVP & CHIEF MEDICAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 93,936 F1 · shares: Represents shares automatically sold pursuant to an irrevocable sell to cover election entered into upon acceptance of the grant to satisfy tax withholding obligations in connection with the vesting of 5,000 RSUs from a January 3, 2025 grant of 20,000 RSUs. Read SEC document |
| January 02, 2026 Filed Jan 6, 2026 22:20 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | GrantStock Option (Right to Buy) · Derivative | 46,875 | $0.00 Strike: $76.74 | $0.00 |
DisclosureSEC source: 0001686217-26-000002 · form4-01062026_050122.xml · derivative · entry 2 Golden Lee Scott · CIK 0001686217 · EVP & CHIEF MEDICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 46,875 Underlying: Common Stock · 46,875 shares Expires 2036-01-01 F3 · derivative.exercise_date: This option was granted on January 2, 2026, and vests over four years, with 25% of the shares underlying the option vesting on January 2, 2027, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning on April 2, 2027. Read SEC document |
| January 02, 2026 Filed Jan 6, 2026 22:20 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | GrantCommon Stock | 18,750 | $0.00 | $0.00 |
DisclosureSEC source: 0001686217-26-000002 · form4-01062026_050122.xml · nonDerivative · entry 1 Golden Lee Scott · CIK 0001686217 · EVP & CHIEF MEDICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 95,276 F1 · shares: Restricted stock units granted on January 2, 2026 that vest in four equal installments over four years, commencing on January 2, 2027. F2 · balance_after: Includes 272 shares of common stock acquired under the Issuer's employee stock purchase plan for the period ended June 30, 2025, and 257 shares of common stock acquired under the Issuer's employee stock purchase plan for the period ended December 31, 2025. Read SEC document |
| December 02, 2025 Filed Dec 4, 2025 01:08 UTC | Cadrenal Therapeutics, Inc. CVKD · Entity 8251 | GrantStock Options · Derivative | 5,000 | $0.00 Strike: $8.27 | $0.00 |
DisclosureSEC source: 0001213900-25-118003 · ownership.xml · derivative · entry 1 Golden Lee Scott · CIK 0001686217 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,000 Underlying: Common Stock · 5,000 shares Expires 2035-12-01 F1 · security: Consists of options to purchase 5,000 shares of common stock, which shall vest 1/3 on January 1, 2027 and thereafter pro rata on a monthly basis over 24 months, subject to the Reporting Person's continued service to the Issuer through each vesting date, having an exercise price equal to the fair market value of the Issuer's common stock on the effective date of the grant. Read SEC document |
| April 02, 2025 Filed Apr 4, 2025 21:20 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 897 | $46.95 | $42,114.15 |
DisclosureSEC source: 0001415889-25-010222 · form4-04042025_050401.xml · nonDerivative · entry 1 Golden Lee Scott · CIK 0001686217 · EVP & CHIEF MEDICAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 75,997 F1 · shares: Represents shares automatically sold pursuant to an irrevocable sell to cover election entered into upon acceptance of the grant to satisfy tax withholding obligations in connection with the vesting of 2,100 RSUs from an April 24, 2023 grant of 8,400 RSUs. Read SEC document |
| February 20, 2025 Filed Feb 21, 2025 22:20 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 962 | $50.12 | $48,219.29 |
DisclosureSEC source: 0001415889-25-005135 · form4-02212025_050206.xml · nonDerivative · entry 2 Golden Lee Scott · CIK 0001686217 · EVP & CHIEF MEDICAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 76,894 F1 · shares: Represents shares automatically sold pursuant to an irrevocable sell to cover election entered into upon acceptance of the grant to satisfy tax withholding obligations in connection with the vesting of 5,000 RSUs from a February 15, 2024 grant of 20,000 RSUs and the vesting of 1,300 RSUs from a February 15, 2024 grant of 2,600 RSUs. Read SEC document |
| February 19, 2025 Filed Feb 21, 2025 22:20 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 795 | $50.10 | $39,826.32 |
DisclosureSEC source: 0001415889-25-005135 · form4-02212025_050206.xml · nonDerivative · entry 1 Golden Lee Scott · CIK 0001686217 · EVP & CHIEF MEDICAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 77,856 F1 · shares: Represents shares automatically sold pursuant to an irrevocable sell to cover election entered into upon acceptance of the grant to satisfy tax withholding obligations in connection with the vesting of 5,000 RSUs from a February 15, 2024 grant of 20,000 RSUs and the vesting of 1,300 RSUs from a February 15, 2024 grant of 2,600 RSUs. Read SEC document |
| January 08, 2025 Filed Jan 10, 2025 22:20 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 1,198 | $44.50 | $53,311.00 |
DisclosureSEC source: 0001415889-25-001292 · form4-01102025_050105.xml · nonDerivative · entry 2 Golden Lee Scott · CIK 0001686217 · EVP & CHIEF MEDICAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 78,651 F2 · shares: Represents shares automatically sold pursuant to irrevocable sell to cover elections entered into upon acceptance of the respective grants to satisfy tax withholding obligations in connection with the vesting of 990 RSUs from a January 6, 2021 grant of 3,960 RSUs and the vesting of 3,539 RSUs from January 7, 2022 grants totaling 14,155 RSUs. Read SEC document |
| January 07, 2025 Filed Jan 10, 2025 22:20 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 810 | $45.34 | $36,725.40 |
DisclosureSEC source: 0001415889-25-001292 · form4-01102025_050105.xml · nonDerivative · entry 1 Golden Lee Scott · CIK 0001686217 · EVP & CHIEF MEDICAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 79,849 F1 · shares: Represents shares automatically sold pursuant to an irrevocable sell to cover election entered into upon acceptance of the grant to satisfy tax withholding obligations in connection with the vesting of 2,666 RSUs from a January 5, 2023 grant of 10,640 RSUs. Read SEC document |
| January 03, 2025 Filed Jan 7, 2025 22:20 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | GrantStock Option (Right to Buy) · Derivative | 50,000 | $0.00 Strike: $46.54 | $0.00 |
DisclosureSEC source: 0001415889-25-001018 · form4-01072025_050107.xml · derivative · entry 2 Golden Lee Scott · CIK 0001686217 · EVP & CHIEF MEDICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2035-01-02 F3 · derivative.exercise_date: This option was granted on January 3, 2025, and vests over four years, with 25% of the shares underlying the option vesting on January 3, 2026, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning on April 3, 2026. Read SEC document |
| January 03, 2025 Filed Jan 7, 2025 22:20 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | GrantCommon Stock | 20,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-001018 · form4-01072025_050107.xml · nonDerivative · entry 1 Golden Lee Scott · CIK 0001686217 · EVP & CHIEF MEDICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 80,659 F1 · shares: Restricted stock units granted on January 3, 2025 that vest in four equal installments over four years, commencing on January 3, 2026. F2 · balance_after: Includes 445 shares of common stock acquired under the Issuer's employee stock purchase plan for the period ended June 30, 2024, and 401 shares of common stock acquired under the Issuer's employee stock purchase plan for the period ended December 31, 2024. Read SEC document |
| May 07, 2024 Filed May 8, 2024 21:20 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 175 | $32.82 | $5,743.50 |
DisclosureSEC source: 0001415889-24-012633 · form4-05082024_050501.xml · nonDerivative · entry 1 Golden Lee Scott · CIK 0001686217 · EVP & CHIEF MEDICAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 59,813 F1 · shares: Represents shares automatically sold pursuant to an irrevocable sell to cover election entered into upon acceptance of the grant to satisfy tax withholding obligations in connection with the vesting of 713 RSUs from a May 11, 2020 grant of 2,850 RSUs. Read SEC document |
| April 02, 2024 Filed Apr 4, 2024 21:16 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 526 | $28.37 | $14,922.62 |
DisclosureSEC source: 0001415889-24-010313 · form4-04042024_090422.xml · nonDerivative · entry 1 Golden Lee Scott · CIK 0001686217 · EVP & CHIEF MEDICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 59,988 F1 · shares: Represents shares automatically sold pursuant to an irrevocable sell to cover election entered into upon acceptance of the grant to satisfy tax withholding obligations in connection with the vesting of 2,100 RSUs from a April 24, 2023 grant of 8,400 RSUs. Read SEC document |
| February 15, 2024 Filed Feb 16, 2024 21:10 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | GrantStock Option (Right to Buy) · Derivative | 50,000 | $0.00 Strike: $25.69 | $0.00 |
DisclosureSEC source: 0001415889-24-004107 · form4-02162024_040242.xml · derivative · entry 3 Golden Lee Scott · CIK 0001686217 · CHIEF MEDICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2034-02-14 F3 · derivative.exercise_date: This option was granted on February 15, 2024, and vests over four years, with 25% of the shares underlying the option vesting on February 15, 2025, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning on May 15, 2025. Read SEC document |
| February 15, 2024 Filed Feb 16, 2024 21:10 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | GrantCommon Stock | 2,600 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-004107 · form4-02162024_040242.xml · nonDerivative · entry 2 Golden Lee Scott · CIK 0001686217 · CHIEF MEDICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 60,514 F2 · shares: Restricted stock units granted on February 15, 2024 that vest in two equal installments over two years, commencing on February 15, 2025. Read SEC document |
| February 15, 2024 Filed Feb 16, 2024 21:10 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | GrantCommon Stock | 20,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-004107 · form4-02162024_040242.xml · nonDerivative · entry 1 Golden Lee Scott · CIK 0001686217 · CHIEF MEDICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 57,914 F1 · shares: Restricted stock units granted on February 15, 2024 that vest in four equal installments over four years, commencing on February 15, 2025. Read SEC document |
| January 09, 2024 Filed Jan 10, 2024 21:06 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 1,225 | $29.01 | $35,543.13 |
DisclosureSEC source: 0001415889-24-000913 · form4-01102024_090125.xml · nonDerivative · entry 2 Golden Lee Scott · CIK 0001686217 · CHIEF MEDICAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 37,914 F3 · shares: Represents shares automatically sold pursuant to irrevocable sell to cover elections entered into upon acceptance of the respective grants to satisfy tax withholding obligations in connection with the vesting of 990 RSUs from a January 6, 2021 grant of 3,960 RSUs and the vesting of 3,539 RSUs from January 7, 2022 grants totaling14,155 RSUs. Read SEC document |
| January 08, 2024 Filed Jan 10, 2024 21:06 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 775 | $28.64 | $22,196.23 |
DisclosureSEC source: 0001415889-24-000913 · form4-01102024_090125.xml · nonDerivative · entry 1 Golden Lee Scott · CIK 0001686217 · CHIEF MEDICAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 39,139 F1 · shares: Represents shares automatically sold pursuant to an irrevocable sell to cover election entered into upon acceptance of the grant to satisfy tax withholding obligations in connection with the vesting of 2,666 RSUs from a January 5, 2023 grant of 10,640 RSUs. F2 · balance_after: Includes 327 shares of common stock acquired under the Issuer's employee stock purchase plan for the period ending June 30, 2023 and 301 shares of common stock acquired under the Issuer's employee stock purchase plan for the period ending December 31, 2023. Read SEC document |
| January 28, 2018 Filed Jan 30, 2018 21:27 UTC | MetaVia Inc. GEMP · Entity 7947 | GrantEmployee Stock Option (right to buy) · Derivative | 148,000 | $0.00 Strike: $10.10 | $0.00 |
DisclosureSEC source: 0001596771-18-000012 · primary_doc.xml · derivative · entry 1 Golden Lee Scott · CIK 0001686217 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 148,000 Underlying: Common Stock · 148,000 shares Expires 2028-01-27 F1 · derivative.exercise_date: The option vests in a series of 48 successive monthly installments on the last day of each month, commencing on the grant date. Read SEC document |
| March 28, 2017 Filed Mar 29, 2017 20:17 UTC | MetaVia Inc. GEMP · Entity 7947 | GrantEmployee Stock Option (right to buy) · Derivative | 20,000 | $0.00 Strike: $11.15 | $0.00 |
DisclosureSEC source: 0001596771-17-000024 · primary_doc.xml · derivative · entry 1 Golden Lee Scott · CIK 0001686217 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2027-03-27 F1 · derivative.exercise_date: The option vests in a series of forty-eight successive equal monthly installments on the last day of each month, commencing on the grant date. Read SEC document |
| October 05, 2016 Filed Oct 6, 2016 20:25 UTC | MetaVia Inc. GEMP · Entity 7947 | GrantEmployee Stock Option (right to buy) · Derivative | 126,000 | $0.00 Strike: $10.80 | $0.00 |
DisclosureSEC source: 0001596771-16-000159 · primary_doc.xml · derivative · entry 1 Golden Lee Scott · CIK 0001686217 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 126,000 Underlying: Common Stock · 126,000 shares Expires 2026-10-04 F1 · derivative.exercise_date: The option vests as to 12,000 shares immediately on the Vesting Commencement Date; one-fourth of the remaining shares vest on the last day of the month on which the one year anniversary of the Vesting Commencement Date occurs; the balance of the shares vest in a series of 36 successive equal monthly installments measured from the last day of the month on which the one year anniversary of the Vesting Commencement Date occurs. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.